|
|
|
| Clinical effect of hormone at different doses combined with Cyclophosphamide pulse therapy in the treatment of membranous nephropathy |
| CAO Shan LIU Yu |
| Department of Nephrology, Pingxiang People′s Hospital, Jiangxi Province, Pingxiang 337000, China |
|
|
|
|
Abstract Objective To investigate the effect of hormone at different doses combined with Cyclophosphamide pulse therapy in the treatment membranous nephropathy.Methods Totally 32 patients with membranous nephropathy admitted into our hospital from January 2016 to June 2018 were selected.They were divided into two groups by a random number table, 16 cases in each group.Both groups received Cyclophosphamide pulse therapy.Based on that, the control group was given a sufficient dose of hormone [1 mg/(kg·d) Prednisolone acetate tablets], and the observation group was given a medium dose of hormone [0.5 mg/(kg·d) Prednisolone acetate tablets].The clinical efficacy, blood lipid indexes, the time of bone mineral density reduction, and adverse reactions were compared between the two groups.Results After treatment, the total remission rate and serum creatinine (Cr) level of the two groups had no significant differences (P＞0.05).After treatment, the total cholesterol (TC), triglycerides (TG) and low-density lipoprotein (LDL) levels were lower than those before treatment, and the levels of TC, TG, and LDL in the observation group were lower than those of the control group, and the differences were statistically significant (P＜0.05).The time of bone mineral density reduction in the observation group was later than that of the control group, and the total incidence of adverse reactions was lower than that of the control group, the differences were statistically significant (P＜0.05).Conclusion Combined with Cyclophosphamide pulse therapy, the adequate-dose hormone treatment and the medium-dose hormone treatment have equivalent effect on membranous nephropathy, but using medium-dose hormone treatment can effectively regulate blood lipid levels, delay the occurrence of osteoporosis, and reduce the incidence of adverse reactions.
|
|
|
|
|
|
| [7] |
刘威，刘昊虹，周兵，等.钙调神经磷酸酶抑制剂与环磷酰胺治疗特发性膜性肾病的疗效分析[J].中国中西医结合肾病杂志，2017，18（4）：338-339.
|
| [8] |
陆晓华，郑亚莉，高永财，等.环孢素联合糖皮质激素对比环磷酰胺联合糖皮质激素治疗膜性肾病有效性与安全性的Meta 分析[J].中国药房，2019，30（10）：1407-1411.
|
| [9] |
郭晓姣，王利华.不同免疫抑制剂治疗特发性膜性肾病的临床疗效比较[J].中国中西医结合肾病杂志，2019，20（6）：514-517.
|
| [10] |
余登，张尚瑜，邓秀清.他克莫司联合糖皮质激素治疗特发性膜性肾病的临床疗效观察[J].实用医院临床杂志，2018，15（2）：41-43.
|
| [1] |
崔诗淇，闻心雨，王艳秋.特发性膜性肾病的治疗新进展[J].医学综述，2018，24（21）：4250-4255.
|
| [2] |
罗建成.特发性膜性肾病患者应用环磷酰胺冲击疗法联合糖皮质激素治疗的临床效果[J].黑龙江医药，2017，30（1）：83.
|
| [3] |
解放军肾脏病研究所学术委员会.特发性膜性肾病的诊断及治疗规范[J].肾脏病与透析肾移植杂志，2004，13（6）：558-559.
|
| [4] |
王宏.特发性膜性肾病患者应用环磷酰胺冲击疗法联合糖皮质激素治疗的临床效果[J].临床医药文献杂志，2017，4（78）：1524.
|
| [5] |
薛明伟，郭更新，刘爱翔，等.单用环孢霉素治疗特发性膜性肾病患者效果观察[J].山东医药，2019，59（11）：69-72.
|
| [6] |
郭艳红，郑丹侠，王悦.年轻人膜性肾病的临床病理特点及治疗效果[J].中国血液净化，2017，16（4）：242-246，272.
|
| [11] |
李争，贾英辉，杨立豹，等.针刺穴位配合甲泼尼龙、环磷酰胺治疗重度膜性肾病35 例疗效观察[J].安徽医药，2018，22（6）：1174-1178.
|
| [12] |
毛文丽，杜琳娜，张真真，等.他克莫司或环磷酰胺联合糖皮质激素治疗特发性膜性肾病的疗效比较[J].临床肾脏病杂志，2018，18（12）：756-760.
|
| [13] |
吴刚，王利平，赵成志，等.环磷酰胺联合小剂量激素治疗膜性肾病的疗效观察及血清PLA2R 25（OH）D3 NGAL 水平变化分析[J].河北医学，2019，25（1）：54-58.
|
| [14] |
贺红光，黄亿芸，曾春，等.环磷酰胺联合糖皮质激素治疗特发性膜性肾病疗效的影响因素分析[J].中华肾脏病杂志，2019，35（1）：9-17.
|
| [15] |
左建娇，赵政，孙汝，等.芪苓通络方联合甲泼尼龙与环磷酰胺治疗特发性膜性肾病中高危患者临床观察[J].中华中医药学刊，2018，36（11）：2723-2725.
|
| [16] |
郭景鸽.小剂量激素联合环孢素A 与环磷酰胺对膜性肾病治疗的临床疗效影响[J].中国药物与临床，2019，19（6）：974-976.
|
| [17] |
娄成利，徐业，黄科，等.健脾益气清热活血法联合不同免疫抑制剂治疗IMN 临床疗效及安全性评估[J].中国现代医生，2019，57（9）：130-133，136.
|
| [18] |
郝海英.注射用红花黄色素联合环孢素A 和泼尼松治疗老年膜性肾病的临床研究[J].现代药物与临床，2017，32（9）：1726-1729.
|
|
|
|
